Fiasp PumpCart (insulin aspart) - supply shortage

Ongoing

insulin aspart

Shortage information

There is a shortage of Fiasp PumpCart in the EU (European Union) / EEA (European Economic Area).

Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes. It contains the active substance insulin aspart, a fast-acting insulin. The Fiasp PumpCart is one of presentations of this medicine.

For further information on the use of the medicine please refer to the medicine’s overview page.

Reason for shortage

The current manufacturing capacity for Fiasp PumpCart cannot meet demand. This has led or may lead to intermittent shortages of Fiasp PumpCart. The shortages are not related to a quality defect of the product or a safety issue.

In addition, the company marketing Fiasp will discontinue Fiasp PumpCart for commercial reasons by the end of 2026 at the latest in all EU/EEA countries where the product is currently marketed.

Member States affected

All Member States where the product is marketed are currently affected or are at risk of being affected by the intermittent shortages: Belgium, Denmark, Finland, France, Germany, Ireland, Luxembourg, Netherlands, Norway, Spain and Sweden.

For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.

Monitoring of shortage

EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the supply shortage and prepare for the discontinuation in 2026.

Recommendations for healthcare professionals

• No new patients should be started on Fiasp PumpCart throughout 2025.
• In case Fiasp PumpCart is unavailable, healthcare professionals should switch existing patients to alternative fast-acting insulin treatment based on existing guidance and clinical judgment. Other fast-acting insulins include:
  • Fiasp, NovoRapid or insulin aspart biosimilars;
  • insulin lispro or its biosimilars;
  • Insulin glulisine or its biosimilars;
• A medicine shortage communication (MSC) has been sent to healthcare professionals in affected Member States and will also be published on the EMA website.
• For additional information, consult your country’s shortage register or contact your national competent authority.

Recommendations for patients and carers

• Contact your healthcare professional well before your current supply runs out.
• If you use Fiasp PumpCart regularly, your healthcare professional will discuss an alternative insulin medicine with you.
• Your healthcare professional will ensure that you are counselled on any changes and provided with adequate training.
• If you have any questions, speak to your doctor or pharmacist.
• For additional information, consult your country’s shortage register or contact your national competent authority. 

Key facts

• Medicines affected:
  Fiasp PumpCart (insulin aspart)
• Supply shortage status:
  Ongoing
• International non-proprietary name (INN) or common name:
  insulin aspart
• Pharmaceutical forms affected:
  Solution for injection in a cartridge
• Strengths affected:
  100 units/mL
• Availability of alternatives:
  Yes

Key dates

• Start of supply shortage:
  08/05/2025
• First published:
  12/05/2025